These experimental results suggested the TSP-1-CD47 interaction and that the key enzymes (PKA and Src) in the intracellular signaling pathways activating integrin α4β1 may become potential targets for RA therapeutics. The gene discussed is SRC; the disease is rheumatoid arthritis.